DK169232B1 - Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling af nyresygdomme - Google Patents

Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling af nyresygdomme Download PDF

Info

Publication number: DK169232B1
Authority: DK; Denmark
Prior art keywords: igf; infusion; pharmaceutical composition; treatment; preparation
Prior art date: 1988-02-05

Application number

DK052089A

Other languages

Danish (da)

English (en)

Other versions

DK52089D0 (da

DK52089A (da

Inventor

Ernst Rudolf Froesch

Hans-Peter Guler

Christoph Schmid

Juergen Zapf

Original Assignee

Ciba Geigy Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-02-05

Filing date

1989-02-03

Publication date

1994-09-19

1989-02-03 Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag

1989-02-03 Publication of DK52089D0 publication Critical patent/DK52089D0/da

1989-08-06 Publication of DK52089A publication Critical patent/DK52089A/da

1994-09-19 Application granted granted Critical

1994-09-19 Publication of DK169232B1 publication Critical patent/DK169232B1/da

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
238000011282 treatment Methods 0.000 title claims abstract description 17
238000004519 manufacturing process Methods 0.000 title claims description 4
208000017169 kidney disease Diseases 0.000 title abstract description 10
230000024924 glomerular filtration Effects 0.000 claims abstract description 17
238000002360 preparation method Methods 0.000 claims abstract description 12
238000001802 infusion Methods 0.000 claims description 56
238000007920 subcutaneous administration Methods 0.000 claims description 18
238000001990 intravenous administration Methods 0.000 claims description 6
210000003734 kidney Anatomy 0.000 claims description 4
238000002054 transplantation Methods 0.000 claims description 4
206010037596 Pyelonephritis Diseases 0.000 claims description 3
208000001647 Renal Insufficiency Diseases 0.000 claims description 3
206010061989 glomerulosclerosis Diseases 0.000 claims description 3
201000006334 interstitial nephritis Diseases 0.000 claims description 3
201000006370 kidney failure Diseases 0.000 claims description 3
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
238000007918 intramuscular administration Methods 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims 1
102100037852 Insulin-like growth factor I Human genes 0.000 abstract description 83
108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract description 5
102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract description 3
230000001225 therapeutic effect Effects 0.000 abstract description 3
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 81
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 36
210000002966 serum Anatomy 0.000 description 23
229940109239 creatinine Drugs 0.000 description 18
210000004369 blood Anatomy 0.000 description 15
239000008280 blood Substances 0.000 description 15
230000037396 body weight Effects 0.000 description 15
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
210000002700 urine Anatomy 0.000 description 12
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
239000008103 glucose Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 8
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
229910052744 lithium Inorganic materials 0.000 description 8
230000036470 plasma concentration Effects 0.000 description 8
241000282472 Canis lupus familiaris Species 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
239000004202 carbamide Substances 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000011734 sodium Substances 0.000 description 6
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 5
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
238000003556 assay Methods 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000029142 excretion Effects 0.000 description 5
238000000034 method Methods 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
229940116269 uric acid Drugs 0.000 description 5
241000282412 Homo Species 0.000 description 4
208000013016 Hypoglycemia Diseases 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
241000700159 Rattus Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000004364 calculation method Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000002218 hypoglycaemic effect Effects 0.000 description 4
230000003907 kidney function Effects 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000000243 solution Substances 0.000 description 4
102000009027 Albumins Human genes 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000006872 improvement Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
230000010245 tubular reabsorption Effects 0.000 description 3
208000035143 Bacterial infection Diseases 0.000 description 2
206010018364 Glomerulonephritis Diseases 0.000 description 2
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
230000009102 absorption Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
239000003978 infusion fluid Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000011630 iodine Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
210000001364 upper extremity Anatomy 0.000 description 2
229940045136 urea Drugs 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
101100097985 Caenorhabditis elegans mars-1 gene Proteins 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
239000006096 absorbing agent Substances 0.000 description 1
239000002390 adhesive tape Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
239000002359 drug metabolite Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
210000004349 growth plate Anatomy 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000009588 inulin clearance Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000003950 pathogenic mechanism Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
210000000512 proximal kidney tubule Anatomy 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
239000003053 toxin Substances 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
239000003643 water by type Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Immunology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)

DK052089A 1988-02-05 1989-02-03 Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling af nyresygdomme DK169232B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP88810071		1988-02-05
EP88810071		1988-02-05

Publications (3)

Publication Number	Publication Date
DK52089D0 DK52089D0 (da)	1989-02-03
DK52089A DK52089A (da)	1989-08-06
DK169232B1 true DK169232B1 (da)	1994-09-19

Family

ID=8200570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK052089A DK169232B1 (da)	1988-02-05	1989-02-03	Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling af nyresygdomme

Country Status (10)

Country	Link
US (1)	US5106832A (de)
EP (1)	EP0327503B1 (de)
JP (1)	JP2783825B2 (de)
KR (1)	KR0131088B1 (de)
AT (1)	ATE86496T1 (de)
AU (1)	AU621583B2 (de)
CA (1)	CA1336400C (de)
DE (1)	DE68905203T2 (de)
DK (1)	DK169232B1 (de)
ZA (1)	ZA89813B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5128320A (en) *	1990-01-18	1992-07-07	Genentech, Inc.	Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
US5374620A (en) *	1990-06-07	1994-12-20	Genentech, Inc.	Growth-promoting composition and its use
US5681814A (en) *	1990-06-07	1997-10-28	Genentech, Inc.	Formulated IGF-I Composition
WO1993019084A1 (en) *	1992-03-24	1993-09-30	Synergen, Inc.	Refolding and purification of insulin-like growth factor i
US5273961A (en) *	1992-09-22	1993-12-28	Genentech, Inc.	Method of prophylaxis of acute renal failure
CA2176709A1 (en) *	1993-11-15	1995-05-26	Howard R. Higley	Method of treating renal disease by administering igf-i and igfbp-3
US6812208B2 (en)	1993-12-23	2004-11-02	Neuronz Ltd.	Methods to improve neural outcome
US5728676A (en) *	1994-09-08	1998-03-17	Ciba-Geigy Corporation	Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5837675A (en) *	1995-02-03	1998-11-17	Brox; Alan G.	Synergistic effect of insulin-like growth factor-I and erythropoietin
US5741776A (en) *	1995-05-22	1998-04-21	Genentech, Inc.	Method of administration of IGF-I
US5565428A (en) *	1995-05-22	1996-10-15	Genentech, Inc.	Method of administration of IGF-I
JPH0995455A (ja) *	1995-09-29	1997-04-08	Sumitomo Pharmaceut Co Ltd	腎機能改善剤
WO1998011913A1 (en) *	1996-09-16	1998-03-26	Dalhousie University	Use of igf-i for the treatment of polycystic kidney disease and related indications
US6025368A (en) *	1997-02-25	2000-02-15	Celtrix Pharmaceuticals, Inc.	Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en)	1997-02-25	2003-02-04	Celtrix Pharmaceuticals, Inc.	Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) *	1997-02-25	2000-01-18	Celtrix Pharmaceuticals, Inc.	Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6420518B1 (en)	1997-04-04	2002-07-16	Genetech, Inc.	Insulin-like growth factor agonist molecules
US6121416A (en)	1997-04-04	2000-09-19	Genentech, Inc.	Insulin-like growth factor agonist molecules
US7074762B2 (en) *	1998-01-05	2006-07-11	Washington University	Composition and method for improving function of embryonic kidney transplants
AU762351B2 (en) *	1999-01-06	2003-06-26	Genentech Inc.	Insulin-like growth factor (IGF) I mutant variants
JP2002535967A (ja) *	1999-01-06	2002-10-29	ジェネンテック・インコーポレーテッド	インシュリン様成長因子（ｉｇｆ）ｉ変異体
ATE389416T1 (de) *	2000-05-16	2008-04-15	Genentech Inc	Behandlung von knorpelerkrankungen
CN100439397C (zh) *	2001-02-09	2008-12-03	基因技术股份有限公司	Igf-1的结晶
US20070004641A1 (en) *	2001-05-24	2007-01-04	Neuren Pharmaceuticals Limited	Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
EP1401808B1 (de)	2001-05-24	2009-07-08	Neuren Pharmaceuticals Limited	Gpe-analoga und peptidomimetika
US7605177B2 (en) *	2001-05-24	2009-10-20	Neuren Pharmaceuticals Limited	Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) *	2001-05-24	2010-05-11	Neuren Pharmaceuticals Limited	Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
JP2008511838A (ja) *	2004-08-30	2008-04-17	テルシカ・インク	インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置
US20210008172A1 (en)	2019-07-11	2021-01-14	Opko Biologics Ltd.	Long-acting igf-1 or igf-1 variants and methods of producing same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ207842A (en) *	1983-04-25	1988-02-12	Chiron Corp	Production of human insulin-like growth factor (igf) using cdna

1989
- 1989-01-26 EP EP89810073A patent/EP0327503B1/de not_active Expired - Lifetime
- 1989-01-26 AT AT89810073T patent/ATE86496T1/de not_active IP Right Cessation
- 1989-01-26 DE DE8989810073T patent/DE68905203T2/de not_active Expired - Lifetime
- 1989-02-01 AU AU28998/89A patent/AU621583B2/en not_active Expired
- 1989-02-02 ZA ZA89813A patent/ZA89813B/xx unknown
- 1989-02-03 JP JP1024104A patent/JP2783825B2/ja not_active Expired - Lifetime
- 1989-02-03 CA CA000590026A patent/CA1336400C/en not_active Expired - Fee Related
- 1989-02-03 DK DK052089A patent/DK169232B1/da not_active IP Right Cessation
- 1989-02-04 KR KR1019890001311A patent/KR0131088B1/ko not_active Expired - Fee Related
1990
- 1990-12-21 US US07/634,772 patent/US5106832A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU621583B2 (en)	1992-03-19
JP2783825B2 (ja)	1998-08-06
KR890012666A (ko)	1989-09-18
DE68905203D1 (de)	1993-04-15
KR0131088B1 (ko)	1998-04-17
EP0327503B1 (de)	1993-03-10
DK52089D0 (da)	1989-02-03
ZA89813B (en)	1989-09-27
ATE86496T1 (de)	1993-03-15
US5106832A (en)	1992-04-21
DK52089A (da)	1989-08-06
EP0327503A1 (de)	1989-08-09
JPH01226827A (ja)	1989-09-11
AU2899889A (en)	1989-08-10
CA1336400C (en)	1995-07-25
DE68905203T2 (de)	1993-07-22

Legal Events

Date	Code	Title	Description
1994-09-19	B1	Patent granted (law 1993)
2009-02-23	PUP	Patent expired

Publication	Publication Date	Title
DK169232B1 (da)	1994-09-19	Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling af nyresygdomme
DK169233B1 (da)	1994-09-19	Anvendelse af IGF I til fremstilling af et farmaceutisk præparat til behandling og forebyggelse af sekundærvirkninger af hyperinsulinæmi hos diabetikere behandlet med insulin
EP0732933B1 (de)	2002-10-09	Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
Hirschberg et al.	1993	Effects of insulin-like growth factor I on renal function in normal men
Johansson et al.	1992	The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients
Sherwin et al.	1976	Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon.
Tsai et al.	1984	Impaired vitamin D metabolism with aging in women. Possible role in pathogenesis of senile osteoporosis.
Pagano et al.	1983	Metformin reduces insulin requirement in type 1 (insulin-dependent) diabetes
Russell et al.	1974	1, 25-Dihydroxycholecalciferol and 1α-hydroxycholecalciferol in hypoparathyroidism
Becker et al.	1972	Patterns of insulin response to glucose in protein-calorie malnutrition
Shmueli et al.	1996	High Insulin–Like Growth Factor Binding Protein 1 Levels in Cirrhosis: Link With Insulin Resistance
Kaplowitz et al.	1982	Radioimmunoassay of vasopressin in familial central diabetes insipidus
Pierach et al.	1980	Hematin therapy in porphyric attacks
US4263283A (en)	1981-04-21	Method for prophylaxis and/or treatment of sickle cell disease
Zimmerman et al.	1987	Survival of diabetic patients on continuous ambulatory peritoneal dialysis for over five years
Fioretto et al.	1992	Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes
Uribarri et al.	1982	Pseudohypoaldosteronism following kidney transplantation
Logie et al.	1976	Hazards of monocomponent insulins
Asano et al.	1982	Insulin delivery rate in response to glucose and arginine infusion in hyperthyroidism
YOKOYAMA et al.	1992	Transient extreme insulin resistance in shock during diabetic ketoacidosis
Krans	1979	Insulin, glucagon and oral hypoglycaemic drugs
DUNBAR JR	1970	STUDIES ON THE EFFECTS OF PROLONGED SULFONYLUREA TREATMENT ON INSULIN SYNTHESIS AND RELEASE IN NORMAL RODENTS
TESSARI et al.	1996	LIVER, PANCREAS, AND BILIARY TRACT
HAYLES et al.	1959	Failure of insulin to induce a change in rate of growth in a 14-year-old boy with anterior pituitary insufficiency
NZ241617A (en)	1997-06-24	Treating and preventing secondary effects of hyperinsulinemia using insulin-like growth factor i (igf i) and lower than normal amounts of insulin